Simplexa C. Auris Direct Assay Launched by Diasorin
Diasorin has launched the Simplexa C. auris Direct kit to aid in identifying Candida auris and enhance infection control.
Diasorin has launched the Simplexa C. auris Direct kit to aid in identifying Candida auris and enhance infection control.
DiaSorin received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Simplexa COVID & Flu A/B Direct assay.
Through the acquisition, DiaSorin will gain access to Luminex’s molecular diagnostics multiplexing technology and a portfolio that will strengthen its existing offering while expanding its presence in the United States.
The product is expected to be CE marked and submitted to the FDA by the end of March 2020 to consider for emergency use authorization.
Read MoreThe moderate-complexity assay is designed to detect varicella-zoster virus DNA from cutaneous and mucocutaneous swab specimens.
Read MoreThe test enables highly automated screening for latent tuberculosis.
Read MoreDiaSorin Molecular has released a new primer pair that targets the yeast Candida auris, for use in creating laboratory-developed molecular tests
Read MoreInclusion of VZV along with HSV-1 and HSV-2 testing may enable clinicians to provide improved therapeutic decisions and advice.
Read MoreThis month’s Product News section features products from Qiagen, ELITechGroup Biomedical Systems, and DiaSorin Molecular.
Read MoreWith clearance for additional sample types, the DiaSorin Molecular Simplexa HSV 1 & 2 assay now claims the most comprehensive sample type coverage for HSV testing on the market.
Read MoreThe offerings join DiaSorin Molecular’s menu of more than 60 molecular reagents for bacterial, fungal, and viral targets.
Read MoreThis month’s issue features laboratory reagents and consumables from such companies as Audit Microcontrols, Bio-rad Laboratories, and Diasorin Molecular.
Read MoreBy purchasing Quest Diagnostics’ immunology and molecular diagnostic products business, DiaSorin looks to boost its presence in the growing market for infectious disease testing.
Read MoreDiaSorin and Beckman Coulter have signed a partnership agreement for distribution of automated hepatitis and HIV tests and instruments in China.
Read More